Huadong Medicine Co (000963) Q4 2023 earnings summary

Executive summary

• Achieved operating revenue of ¥40.62 billion in 2023, up 7.71% year-over-year, with net profit attributable to shareholders at ¥2.84 billion, up 13.59% year-over-year.

• Four major business segments—pharmaceutical industry, pharmaceutical business, aesthetic medicine, and industrial microbiology—contributed to historical breakthroughs in revenue and profit.

• Significant R&D progress with over 60 innovative product lines, 9 in late-stage clinical or regulatory review, and annual R&D investment exceeding ¥2.29 billion.

• Launched Liraglutide Injection (Liluping®), the first liraglutide biosimilar in China, and advanced multiple innovative and biosimilar medicines toward commercialization.

• Expanded international presence, especially in aesthetic medicine, with Sinclair achieving its first annual profit and global product launches.

Financial highlights

• Operating revenue: ¥40.62 billion (+7.71% YoY); net profit attributable to shareholders: ¥2.84 billion (+13.59% YoY).

• Gross margin: 32.40% (up 0.5 percentage points YoY); net cash flow from operating activities: ¥3.93 billion (+64.96% YoY).

• Total assets: ¥33.51 billion; net assets attributable to shareholders: ¥21.05 billion; asset-liability ratio: 35.60%.

• Basic EPS: ¥1.6219; weighted average ROE: 13.96%.

• Proposed cash dividend: ¥1.02 billion (5.8 yuan per 10 shares).

Outlook and guidance

• Focus on innovative medicine, especially in oncology, endocrinology, and autoimmunity, with continued R&D investment and product pipeline expansion.

• Aesthetic medicine segment to pursue global expansion and high-end market positioning.

• Industrial microbiology to accelerate international market entry and product innovation.

• Pharmaceutical business to optimize structure, expand retail and out-of-hospital markets, and enhance profitability.